drugset / Trial / NCT06198686
An Evaluation of The Absolute Bioavailability of TH104
RandomizedCrossoverOpen-labelOther
Summary
This is a single-dose, single-center, open-label, randomized, 2-way crossover study (2 treatments, 2 periods and 2 sequences) of a buccal formulation of Nalmefene 16 mg and a 1 mg intravenous dose of nalmefene injection, with a least 7 days washout period between doses.
Timeline
- Start
- 2024-01-26
- Primary completion
- 2024-02-11
- Completion
- 2024-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nalmefene | Small molecule | 1 mg | Other |
| Subject | Nalmefene | Small molecule | 16 mg | Other |
Indications
No indication recorded.